Quantification of infant exposure to celecoxib through breast milk.
OBJECTIVE
To determine the milk-to-plasma (M/P) concentration ratio of celecoxib, and estimate likely infant exposure.


METHODS
Blood and milk were sampled for 48 h after oral administration of celecoxib 200 mg to six lactating volunteers. The M/P ratio was derived from the area under the concentration-time curves (0-infinity) and the infant 'dose' estimated from celecoxib concentrations in milk.


RESULTS
The median (range) M/P ratio was 0.18 (0.15-0.26). The median (range) infant 'dose' was 0.23% (0.17-0.30%) of the maternal dose, adjusted for weight.


CONCLUSIONS
The relative 'dose' of celecoxib to which infants are exposed via milk is very low, suggesting that breastfeeding during routine dosing would pose minimal risk.
Gardiner
Sharon J
SJ
Department of Clinical Pharmacology, Christchurch Hospital and Christchurch School of Medicine, Christchurch, New Zealand. sharon.gardiner@cdhb.govt.nz
Doogue
Matthew P
MP
Zhang
Mei
M
Begg
Evan J
EJ
D000284:Administration, Oral; D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000032:analysis / Q000493:pharmacokinetics; D019540:Area Under Curve; D000068579:Celecoxib; D016861:Cyclooxygenase Inhibitors / Q000008:administration & dosage / Q000032:analysis / Q000493:pharmacokinetics*; D004781:Environmental Exposure / Q000009:adverse effects; D005260:Female; D006801:Humans; D007223:Infant; D007774:Lactation; D008895:Milk, Human / Q000737:chemistry*; D009035:Mothers; D011720:Pyrazoles / Q000008:administration & dosage / Q000032:analysis / Q000493:pharmacokinetics*; D013449:Sulfonamides / Q000008:administration & dosage / Q000032:analysis / Q000493:pharmacokinetics*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D016861:Cyclooxygenase Inhibitors; D011720:Pyrazoles; D013449:Sulfonamides; D000068579:Celecoxib